3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Glioblastoma
6
Breast Neoplasms
4
Neoplasm Metastasis
3
Glioma
3
Colorectal Neoplasms
3
Central Nervous System Neoplasms
3
Astrocytoma
3
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Recurrence
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pancreatic Neoplasms
2
Neoplasms
2
Gliosarcoma
2
Esophageal Squamous Cell Carcinoma
2
Esophageal Neoplasms
2
Brain Neoplasms
2
Adenocarcinoma Of Esophagus
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Rectal Neoplasms
1
Pinealoma
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neuroblastoma
1
Meningioma
1
Medulloblastoma
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Interventions
Ipilimumab
5
pembrolizumab
3
Nivolumab
3
Paclitaxel
2
Oxaliplatin
2
Doxorubicin
2
Capecitabine
2
CTLA-4 Antigen
2
tremelimumab
1
trastuzumab deruxtecan
1
tebentafusp
1
spartalizumab
1
lenvatinib
1
eribulin
1
envafolimab
1
durvalumab
1
Vemurafenib
1
Surgical Procedures, Operative
1
Radiotherapy
1
Radiosurgery
1
Radiation
1
Leucovorin
1
Immunotherapy
1
Fluorouracil
1
Docetaxel
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Diabetes Mellitus, Insulin-Dependent, 12
×
Surgical Procedures, Operative
×
Clear all
NCT03116529
2024-11-04
NEXIS
University of Maryland, Baltimore
Phase 1/2
Terminated
22 enrolled